Identification of Critical Residues of the MyD88 Death Domain Involved in the Recruitment of Downstream Kinases*
暂无分享,去创建一个
C. Sette | V. Ruggiero | R. De Santis | P. Carminati | G. Gallo | Maria Loiarro | N. Fantò
[1] M. Fischer,et al. Toll‐like Receptors in Autoimmunity , 2008, Annals of the New York Academy of Sciences.
[2] T. Billiar,et al. β2-Integrin-induced p38 MAPK Activation Is a Key Mediator in the CD14/TLR4/MD2-dependent Uptake of Lipopolysaccharide by Hepatocytes* , 2008, Journal of Biological Chemistry.
[3] A. Chaudhary,et al. Targeting toll-like receptor signaling pathways for design of novel immune therapeutics. , 2008, Current drug discovery technologies.
[4] M. Lederman,et al. Human β-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2 , 2007, Proceedings of the National Academy of Sciences.
[5] Grazia Gallo,et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound , 2007, Journal of leukocyte biology.
[6] R. Wait,et al. Mass Spectrometric Analysis of the Endogenous Type I Interleukin-1 (IL-1) Receptor Signaling Complex Formed after IL-1 Binding Identifies IL-1RAcP, MyD88, and IRAK-4 as the Stable Components* , 2007, Molecular & Cellular Proteomics.
[7] Yaniv Ziv,et al. Toll-like receptors modulate adult hippocampal neurogenesis , 2007, Nature Cell Biology.
[8] A. Gearing. Targeting toll‐like receptors for drug development: a summary of commercial approaches , 2007, Immunology and cell biology.
[9] K. Tracey,et al. Hemorrhagic Shock Induces NAD(P)H Oxidase Activation in Neutrophils: Role of HMGB1-TLR4 Signaling1 , 2007, The Journal of Immunology.
[10] K. Resch,et al. The death domain of IRAK-1: an oligomerization domain mediating interactions with MyD88, Tollip, IRAK-1, and IRAK-4. , 2007, Biochemical and biophysical research communications.
[11] H. H. Park,et al. The death domain superfamily in intracellular signaling of apoptosis and inflammation. , 2007, Annual review of immunology.
[12] J. Tavernier,et al. MAPPIT analysis of TLR adaptor complexes , 2007, FEBS letters.
[13] C. Sette,et al. Peptide-mediated Interference of TIR Domain Dimerization in MyD88 Inhibits Interleukin-1-dependent Activation of NF-κB* , 2005, Journal of Biological Chemistry.
[14] L. O’Neill. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. , 2003, Current opinion in pharmacology.
[15] T. Bártfai,et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. Banchereau,et al. Pyogenic Bacterial Infections in Humans with MyD88 Deficiency , 2003, Science.
[17] K. Burns,et al. Inhibition of Interleukin 1 Receptor/Toll-like Receptor Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its Failure to Recruit IRAK-4 , 2003, The Journal of experimental medicine.
[18] S. Janssens,et al. A universal role for MyD88 in TLR/IL-1R-mediated signaling. , 2002, Trends in biochemical sciences.
[19] Holger Wesche,et al. IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Flavell,et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.
[21] C. Weber,et al. The death domain superfamily: a tale of two interfaces? , 2001, Trends in biochemical sciences.
[22] G. Stark,et al. IL-1-induced NFκB and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK) , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[23] A Sankar,et al. The three-dimensional solution structure and dynamic properties of the human FADD death domain. , 2000, Journal of molecular biology.
[24] S. Sprang,et al. Three-Dimensional Structure of a Complex between the Death Domains of Pelle and Tube , 1999, Cell.
[25] G. Stark,et al. IRAK-M Is a Novel Member of the Pelle/Interleukin-1 Receptor-associated Kinase (IRAK) Family* , 1999, The Journal of Biological Chemistry.
[26] Young In Park,et al. The Solution Structure of FADD Death Domain , 1999, The Journal of Biological Chemistry.
[27] R. Boltz,et al. Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. , 1998, The Journal of biological chemistry.
[28] C. Janeway,et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. , 1998, Molecular cell.
[29] F. Martinon,et al. MyD88, an Adapter Protein Involved in Interleukin-1 Signaling* , 1998, The Journal of Biological Chemistry.
[30] Z. Cao,et al. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. , 1997, Immunity.
[31] P. Feng,et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. , 1997, Science.
[32] G. Hardiman,et al. Molecular characterization and modular analysis of human MyD88. , 1996, Oncogene.
[33] Z. Cao,et al. IRAK: A Kinase Associated with the Interleukin-1 Receptor , 1996, Science.
[34] J. Tschopp,et al. The death domain motif found in Fas (Apo‐1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance , 1995, FEBS letters.
[35] A. Kimchi,et al. The death domain: a module shared by proteins with diverse cellular functions. , 1995, Trends in biochemical sciences.
[36] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[37] D. Hultmark. Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family. , 1994, Biochemical and biophysical research communications.
[38] L. Tartaglia,et al. A novel domain within the 55 kd TNF receptor signals cell death , 1993, Cell.
[39] D. Liebermann,et al. Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, Jun-B and histone variants. , 1990, Oncogene.
[40] N. Guex,et al. SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.
[41] Hao Wu,et al. Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .